Genetic insights into drug targets for alzheimer's disease: integrative multi-omics analysis.

ABSTRACT:

Background

The development of effective disease-modifying therapies for Alzheimer's disease (AD) remains a critical unmet need. While Mendelian randomization (MR) has been leveraged to identify genetic variants to accelerate AD target discovery, previous studies have been limited by narrow phenotypic coverage, insufficient multiomics validation, and inadequate mechanistic exploration. This study aims to overcome these limitations via comprehensive MR to identify robust therapeutic targets.

Methods

We performed an integrative multiomics MR analysis leveraging over 50 genome-wide association study (GWAS) datasets spanning AD, cerebrospinal fluid (CSF) biomarkers (Aβ42, p-tau), neuroimaging endophenotypes, cognitive traits, and risk factors. Blood/CSF/brain protein quantitative

SUBMITTER: Liu X 

PROVIDER: S-EPMC12681122 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature